Knoll Capital Management, LLC Annovis Bio, Inc. Transaction History
Knoll Capital Management, LLC
- $160 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding ANVS
# of Institutions
52Shares Held
1.2MCall Options Held
779KPut Options Held
1.77M-
Vanguard Group Inc Valley Forge, PA358KShares$2.06 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA250KShares$1.44 Million0.01% of portfolio
-
Black Rock Inc. New York, NY97.6KShares$562,3430.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA72.6KShares$418,1870.0% of portfolio
-
Geode Capital Management, LLC Boston, MA70.8KShares$407,7560.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $47M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...